Want to see KR:005500 full AI Analyst Report?
Samjin Pharmaceutical Co., Ltd. (005500) Stock Price & Analysis
005500 Stock Chart & Stats
- Day’s Range
- KRW 19,080.00 - KRW 19,360.00
- 52-Week Range
- KRW 16,580.00 - KRW 25,900.00
- Previous Close
- KRW 19,370.00
- Volume
- N/A
- Average Volume (3M)
- 28.77K
- Market Cap
- KRW 225.66B
- Enterprise Value
- KRW 347.35B
- Total Cash (Recent Filing)
- KRW 20.88B
- Total Debt (Recent Filing)
- KRW 129.88B
- Price to Earnings (P/E)
- 10.3
- Beta
- 0.10
- Next Earnings
- Nov 18, 2026 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Dec 29, 2025
- Dividend Yield
- 4.16%
Bulls Say, Bears Say
Bulls Say
Integrated Pharmaceutical Platform
Samjin combines research, development, manufacturing, and marketing across prescription and over-the-counter medicines. This integrated operating model can support product continuity, internal capabilities, and control over commercialization as the company develops and maintains its domestic portfolio.
Long-term Revenue Expansion
Revenue has expanded materially over the longer term, rising from about KRW 250 billion in 2021 to KRW 309 billion in 2025. Although recent growth has moderated, the multi-year increase indicates that the company has continued to build sales across its pharmaceutical portfolio.
Moderate Leverage And Improved Cash Flow
Moderate leverage and recently positive free cash flow provide a more stable foundation for ongoing operations and investment. Debt-to-equity near 0.43 is described as not excessive for the sector, while improved cash generation strengthens financial flexibility relative to prior periods.
Bears Say
Negative Operating Profitability
The shift to slightly negative TTM operating income shows that gross profit is not currently translating into operating earnings. If this persists, cost pressure could limit internal funding for development and marketing while weakening the durability of the company’s earnings profile.
Volatile Free Cash Flow
Although TTM free cash flow has improved, the history of negative free cash flow across several years indicates uneven cash conversion through the cycle. Such volatility can make investment planning less predictable and increase reliance on operating improvements to sustain funding capacity.
Slowing Growth And Reduced Returns
Recent revenue momentum has weakened, and returns on equity have cooled from the stronger 2024 level to roughly 8%. Together, these trends suggest that the existing asset base is producing less incremental profitability, potentially constraining the pace of durable earnings growth.
005500 FAQ
What was Samjin Pharmaceutical Co., Ltd.’s price range in the past 12 months?
What is Samjin Pharmaceutical Co., Ltd.’s market cap?
When is Samjin Pharmaceutical Co., Ltd.’s upcoming earnings report date?
How were Samjin Pharmaceutical Co., Ltd.’s earnings last quarter?
Is Samjin Pharmaceutical Co., Ltd. overvalued?
Does Samjin Pharmaceutical Co., Ltd. pay dividends?
What is Samjin Pharmaceutical Co., Ltd.’s EPS estimate?
How many shares outstanding does Samjin Pharmaceutical Co., Ltd. have?
What happened to Samjin Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Samjin Pharmaceutical Co., Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Samjin Pharmaceutical Co., Ltd.
Samjin Pharmaceuticals Co., Ltd. is a South Korean company focused on the discovery and development of pharmaceutical products. Their current portfolio includes SA001, a Phase II clinical asset targeting dry eye and Sjögren's syndrome. In the preclinical stage, they are advancing SJP1803/1804 for macular degeneration, alongside SJP601 and SJP1602, which are designed to combat cancer. Additionally, SPJ1604 and SPJ003 are in clinical phases for treating cancer and diabetes. A broader range of candidates, including SJP1901, SJP1902, SJP1801, and SJP006, are undergoing biological testing for potential applications across cancer, fibrosis, cancer immunotherapy, Alzheimer's disease, Parkinson's disease, and anti-viral conditions. The company was founded in 1968 and is based in Seoul, South Korea.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Kyu Seok Cho
- Employees
- 819
- Website
- www.samjinpharm.co.kr
- Address
- 121 Wausan Ro, Seoul, SL, 04054, KR
Samjin Pharmaceutical Co., Ltd. (005500) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 5 | 8 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 6 | 0 | 6 |
